Keros Therapeutics (KROS)
NASDAQ:KROS
Top Page
Keros Therapeutics
(NASDAQ:KROS)
Select Model
Select Model
Rating:57Neutral
Price Target:
$11.50
▲(8.39% Upside)
Action:ReiteratedDate:03/09/26
The score is driven primarily by improved 2025 financial performance (profitability and free cash flow turning positive with low leverage), offset by very weak technicals (price far below key moving averages and bearish momentum). Valuation is supportive with a low P/E, and recent corporate events add modest positive pipeline momentum.
Positive Factors
Low leverage / balance sheet flexibility
Very low reported leverage gives Keros flexibility to fund clinical programs, pursue partnerships or M&A, and absorb development setbacks without high interest burden. Over the next 2–6 months this balance sheet strength supports strategic optionality and lowers solvency risk while the pipeline advances.
Negative Factors
Highly volatile revenue profile
A dramatic single-year revenue swing suggests revenues may be driven by non-recurring events (milestones, one-offs) rather than sustainable product sales. This volatility undermines the durability of reported profitability and makes forward cash-flow forecasting and operational planning risky absent repeatable revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet flexibility
Very low reported leverage gives Keros flexibility to fund clinical programs, pursue partnerships or M&A, and absorb development setbacks without high interest burden. Over the next 2–6 months this balance sheet strength supports strategic optionality and lowers solvency risk while the pipeline advances.
Read all positive factors
Keros Therapeutics (KROS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$209.20M
Dividend YieldN/A
Average Volume (3M)489.08K
Price to Earnings (P/E)8.7
Beta (1Y)0.87
Revenue Growth37798.31%
EPS GrowthN/A
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.86
Shares Outstanding19,717,533
10 Day Avg. Volume618,672
30 Day Avg. Volume489,085
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda1.50
Forecast
1Y Price Target
$22.17Price Target Upside108.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.74
Revenue Forecast (FY)$11.48M
Keros Therapeutics Business Overview & Revenue Model
Company Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical ...
How the Company Makes Money
Keros Therapeutics generates revenue primarily through the development and eventual commercialization of its therapeutic candidates. The company does not currently have products on the market; however, it aims to monetize its pipeline through part...
Keros Therapeutics Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 244.06M | 3.55M | 151.00K | 0.00 | 20.10M |
| Gross Profit | 242.55M | 3.55M | 151.00K | 0.00 | 20.10M |
| EBITDA | 72.13M | -185.82M | -152.18M | -104.00M | -56.35M |
| Net Income | 87.01M | -187.35M | -152.99M | -104.68M | -58.74M |
Balance Sheet | |||||
| Total Assets | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M |
| Cash, Cash Equivalents and Short-Term Investments | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M |
| Total Debt | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M |
| Total Liabilities | 34.89M | 44.33M | 37.81M | 29.36M | 12.08M |
| Stockholders Equity | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M |
Cash Flow | |||||
| Free Cash Flow | 105.95M | -162.80M | -126.97M | -71.30M | -63.17M |
| Operating Cash Flow | 107.50M | -160.87M | -124.51M | -70.06M | -62.15M |
| Investing Cash Flow | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M |
| Financing Cash Flow | -378.47M | 391.82M | 178.96M | 120.31M | 28.55M |
Keros Therapeutics Technical Analysis
Negative
10.61
Price Trends
15.03
Negative
16.93
Negative
15.83
Negative
Market Momentum
-1.19
Negative
27.23
Positive
48.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Negative. The current price of 10.61 is below the 20-day moving average (MA) of 11.55, below the 50-day MA of 15.03, and below the 200-day MA of 15.83, indicating a bearish trend. The MACD of -1.19 indicates Negative momentum. The RSI at 27.23 is Positive, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KROS.
Keros Therapeutics Risk Analysis
Keros Therapeutics disclosed 79 risk factors in its most recent earnings report. Keros Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Keros Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $209.20M | 8.71 | 14.25% | ― | 37798.31% | ― | |
56 Neutral | $619.11M | 125.48 | 5.46% | ― | ― | ― | |
56 Neutral | $1.16B | -5.93 | -27.17% | ― | ― | -103.95% | |
54 Neutral | $990.13M | -37.98 | -224.17% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.54B | -15.28 | -64.41% | ― | ― | ― | |
47 Neutral | $1.52B | -5.54 | -57.51% | ― | 48.32% | -1.91% |
* Healthcare Sector Average
KROS
Keros Therapeutics
10.61
0.42
4.12%
GYRE
Gyre Therapeutics
6.78
-0.94
-12.18%
KALV
KalVista Pharmaceuticals
19.33
7.79
67.50%
PVLA
Palvella Therapeutics
112.37
84.38
301.46%
NRIX
Nurix Therapeutics
14.76
2.88
24.24%
BCAX
Bicara Therapeutics Inc.
18.37
5.34
40.98%
Keros Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
Positive
Mar 9, 2026
On March 9, 2026, Keros Therapeutics announced it has entered into an agreement with Massachusetts General Hospital to design a Phase 2 clinical trial of its lead drug candidate rinvatercept for amyotrophic lateral sclerosis within the Healey ALS ...
Business Operations and Strategy
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
Positive
Mar 4, 2026
On March 4, 2026, Keros Therapeutics updated its corporate presentation for use in meetings with investors, analysts and other stakeholders, making it available on its website. The presentation outlines the company’s strategy to leverage TGF...
Executive/Board Changes
Keros Therapeutics Adds Veteran Finance Leader to Board
Positive
Feb 26, 2026
On February 24, 2026, Keros Therapeutics’ board appointed former Lyell Immunopharma CFO and veteran healthcare investment banker Charles Newton as a Class III director, effective March 9, 2026, with a term running through the 2026 annual mee...
Business Operations and Strategy
Keros Therapeutics CEO to Present at Multiple Conferences
Positive
Feb 18, 2026
On February 18, 2026, Keros Therapeutics announced that President and CEO Jasbir S. Seehra will represent the company at three major healthcare investor conferences in late February and early March 2026. He is scheduled for a corporate presentatio...
Business Operations and StrategyProduct-Related Announcements
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
Positive
Jan 9, 2026
On January 9, 2026, Keros Therapeutics updated its corporate presentation for investors and analysts, outlining the company’s strategic focus on TGF-β superfamily modulation and highlighting its lead investigational asset, rinvatercept ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.